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and CD38 expression). Plasma levels of CCL2, CCL4 and
CX 3 CL1 closely resembled the cell numbers of CM, IM and 
NCM, respectively. Our study provides critical insights into 
the earliest stages of acute inflammation and emphasizes 
the necessity to stain for different monocyte subsets when 
studying the role of monocytes in disease, as neither func-
tion nor kinetics of the subsets overlap. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Monocytes perform several roles in acute inflamma-
tion: they are capable of antigen presentation and phago-
cytosis of pathogens and can produce large amounts of 
pro- and anti-inflammatory cytokines  [1] . At least 3 
monocyte subsets have been identified: CD14 ++ /CD16 – 
classical monocytes (CM), CD14 ++ /CD16 + intermediate 
monocytes (IM) and CD14 + /CD16 ++ non-classical mono-
cytes (NCM)  [2] . The subsets have different functionality, 
with CM displaying superior phagocytic capacity, IM dis-
playing superior cytokine production and NCM display-
ing patrolling behaviour on blood vessel walls  [3] . The 3 
subsets display differential expression of chemokine re-
ceptors  [4] , with CM expressing high levels of chemokine 
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 Abstract 
 Three human monocyte subsets are recognized with differ-
ent functions in the immune system: CD14 ++ /CD16 – classical 
monocytes (CM), CD14 ++ /CD16 + intermediate monocytes 
(IM) and CD14 + /CD16 ++ non-classical monocytes (NCM). In-
creased IM and NCM percentages have been reported under 
inflammatory conditions, yet little is known about monocyte 
subsets at the onset of inflammation. The human endotox-
emia model is uniquely capable of studying the first phases 
of acute inflammation induced by intravenous injection of
2 ng/kg bodyweight lipopolysaccharide (LPS) into healthy 
volunteers. After that, monocyte subset counts, activation/
differentiation status and chemokine levels were studied 
over 24 h. The numbers of all subsets were decreased by 
>95% after LPS injection. CM numbers recovered first (3–
6 h), followed by IM (6–8 h) and NCM numbers (8–24 h). Sim-
ilarly, increased monocyte counts were observed first in CM 
(8 h), followed by IM and NCM (24 h). Monocytes did not dis-
play a clear activated phenotype (minor increase in CD11b 
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C-C motif receptor 2 (CCR2), IM expressing high levels 
of CCR5 and NCM expressing high levels of chemokine 
C-X3-C motif receptor 1 (CX 3 CR1). Thus, they respond 
differently to the ligands of these receptors, being chemo-
kine C-C motif ligand 2 (CCL2; also known as MCP1), 
CCL3/CCL4 (also known as MIP-1α/β) and chemokine 
C-X3-C motif ligand 1 (CX 3 CL1; also known as fractal-
kine), respectively  [5] .
 Under homeostatic conditions, most monocytes in the 
peripheral blood belong to the CM subset, followed by 
NCM and with IM being the subset with the lowest fre-
quency. During inflammatory conditions, such as sepsis 
 [6, 7] , bacterial  [8] or viral  [9–11] infections and a wide 
range of inflammatory diseases (reviewed by  [1] ), the fre-
quency of IM or both IM and NCM is increased. How-
ever, as patients with inflammation cannot be identified 
before displaying clinical symptoms, little is known about 
the monocyte subsets during the earliest stages of inflam-
mation.
 The human endotoxemia model allows studying of the 
mechanisms operational in vivo at the initiation of acute 
inflammation. In this model, healthy volunteers are in-
jected with a low dose of 2 ng/kg bodyweight lipopolysac-
charide (LPS), leading to a rapid induction of systemic 
inflammatory symptoms  [12] . Using this model, we have 
previously shown that large numbers of monocytes are 
transiently lost from the circulation after LPS injection 
 [13] . In addition, the number of all 3 subsets has been 
shown to be reduced 2 h after LPS injection, whereas the 
number of IM was increased 24 h after LPS injection  [14] . 
However, a more detailed analysis is required to reveal 
differences in kinetics of the 3 monocyte subsets and their 
associated chemokines early in inflammation.
 Therefore, we determined (1) the kinetics of the 3 hu-
man monocyte subsets after LPS injection, (2) subset-spe-
cific chemokine plasma concentrations and (3) differenc-
es in monocyte activation by single- and multidimension-
al flow cytometry.
 Materials and Methods 
 Subjects and Ethics 
 Samples were obtained from healthy volunteers participating 
in a human endotoxemia trial (ClinicalTrials.gov identifier 
NCT02629874) as published previously  [13] . The study was ap-
proved by the ethics review board of the Radboud University Med-
ical Center in Nijmegen, The Netherlands. It was in compliance 
with the Declaration of Helsinki (adapted by the World Medical 
Association General Assembly, Fortaleza, Brazil, 2013), the Dutch 
rulings on Medical Research Involving Human Subjects Act 
(WMO) and ICH Good Clinical Practice Guidelines. Written in-
formed consent was obtained from all study participants. Male 
subjects 19–24 years of age were healthy as determined by physical 
examination, electrocardiography and haematological laboratory 
values. Subjects with febrile illness in the 2 weeks before the study 
and subjects taking prescription drugs were excluded from the 
study. Subjects were asked to refrain from caffeine and alcohol use 
in the 24 h prior to the experiment and refrain from food intake
12 h prior to the experiment.
 Experimental Endotoxemia Model 
 LPS challenge was performed as published previously  [15] . In 
short, subjects were admitted to the research medium care unit of 
the Radboud Medical Center in the Netherlands. From t = –1 h to 
t = 0, subjects were infused with hydration fluid (2.5% glucose/
0.45% saline at a continuous rate of 1.5 L/h) through a cannula 
placed in an antecubital vein. At t = 0, a single dose of 2 ng/kg 
bodyweight LPS (US standard reference  Escherichia coli O:113, 
NIH Pharmaceutical Development Section, Bethesda, MD, USA) 
was administered. After LPS injection, subjects were infused with 
hydration fluid at a constant rate of 150 mL/h. Heart rate and blood 
pressure were constantly monitored from t = –1 h until discharge 
at t = 8 h, as well as the course of LPS-induced symptoms  [16] .
 Sample Preparation 
 Blood from 6 subjects was collected in sodium heparin tubes 5 
min before LPS injection and at 1.5, 3, 4, 6 and 24 h after LPS injec-
tion and from 5 additional subjects at –5, 15, 30, 60 and 90 min 
after LPS injection ( Fig. 1 ). Absolute differential counts were deter-
mined using a Cell-DYN Emerald Hematology Analyzer (Abbott 
Diagnostics, Abbott Park, IL, USA). Erythrocytes were lysed in ice-
cold isotonic erythrocyte lysis buffer (150 m M NH 4 Cl, 10 m M 
KHCO 3 and 0.1 m M Na 2 EDTA), after which resulting leukocyte 
preparations were washed and resuspended in FACS staining buf-
fer (PBS supplemented with 0.32% trisodium citrate and 10% hu-
man pasteurized plasma solution, both from Sanquin, Amsterdam, 
The Netherlands) at a concentration of 1 × 10 5 cells/μL. Antibodies 
used were anti-CD64-Pacific Blue, CD3-Brilliant Violet (BV) 510, 
CD19-BV510, CD56-BV510, CD86-BV605, CD62L-BV650, CD16-
BV785, CX 3 CR1-FITC, CD303-PerCP-Cy5.5, CD1c-APC-Cy7 (all 
from BioLegend, San Diego, CA, USA), CD80-V450, human leu-
kocyte antigen – antigen D related (HLA-DR)-BV605, CD163-
Alex647, CD69-PC7 (BD Biosciences, San José, CA, USA), CCR2-
PE (R&D Systems, Minneapolis, MN, USA), CD38-PC7 (Thermo 
Fisher Scientific, Waltham, MA, USA), and CD14-ECD (Beckman 
Coulter, Pasadena, CA, USA). After staining, samples were washed 
in FACS staining buffer and fixed for 20 min in a 1% formaldehyde 
solution in PBS. Samples were analysed using a BD LSRFortessa 
flow cytometer (BD Biosciences).
 Flow Cytometric Analysis 
 Monocytes were identified by the following gating strategy: 
cells were gated on forward scatter (FSC) high /sideward scatter 
(SSC) low . Next, T cells, B cells and NK cells were excluded based on 
CD3, CD19 and CD56 expression. Monocyte subsets were identi-
fied as CD14 ++ /CD16 – (CM), CD14 ++ /CD16 + (IM) and CD14 + /
CD16 ++ (NCM) ( Fig.  2 c). Absolute monocyte subset numbers 
were calculated using the absolute granulocyte counts as deter-
mined on a Cell-DYN Emerald Hematology Analyzer and the ra-
tio of SSC high /CD16 ++ neutrophil numbers compared to mono-
cyte subset numbers. On average, more than 3 × 10 5 events were 
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 Fig. 1. Study outline and differential counts after lipopolysaccha-
ride (LPS) injection. Study design ( a ) shows the moment of blood 
withdrawal after injection of LPS. White symbols indicate blood 
withdrawal only for analysis of cell counts; grey symbols indicate 
blood withdrawal for full flow cytometric analysis. Whole white 
blood cell (WBC) counts ( b ) and granulocyte counts are increased 
at 3–8 h after LPS injection, whereas lymphocyte numbers remain 
similar throughout the experiment. Total monocyte counts ( c ) are 
decreased at 1–1.5 h after LPS injection, and cell count increases at 
6–8 h after LPS injection. Monocyte subset percentages ( d ) show 
that classical monocytes (CM) comprise 80–90% of all monocytes 
during most of the experiment. CM counts ( e ) follow those of total 
monocytes. Intermediate monocyte (IM) and non-classical mono-
cyte (NCM) numbers are decreased 1–8 h after LPS injection with 
a trend towards higher IM counts and percentage at 24 h after LPS 
injection.  * ,  * * ,  * * * and  * * * * indicate  p < 0.05,  p < 0.01,  p < 0.001 
and  p < 0.0001 compared to t = 0, respectively. Data indicate me-
dians ± interquartile ranges.  n = 11 for t = 0 and t = 1.5 h;  n = 5 for 
t = 0.25–1 h;  n = 6 for t = 3–24 h. 
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recorded in the monocyte gate. Samples with very low monocyte 
counts (1 volunteer at t = 90 min, 1 at t = 180 min and 1 at t = 360 
min) were compared to other samples at the same time point but 
did not show aberrant median fluorescence intensities (MFIs).
 Multidimensional single-cell analysis was performed by princi-
pal component analysis (PCA) on log-normalized MFIs of CD3/
CD19/CD56-negative cells in the monocyte FSC/SSC gate as de-
scribed by Jansen et al.  [17] with a few modifications. In short, sin-
gle-cell fluorescence intensities were extracted from fcs files using 
FCS Express V5 (De Novo Software, Glendale, CA, USA). For each 
volunteer, data from all time points were combined and log nor-
malized. Subsequently, PCA was performed using the  prcomp func-
tion of R version 3.1.1, with results centred at 0 and variables scaled 
to have unit variance. This results in a so-called object score for 
each cell in each of the 2 PCs, which were plotted using the smooth-
Scatter  function. Since for each cell the computed object scores, the 
original MFIs and the time point are known, traditional gating on 
CD14/16 ( Fig. 2 d) could be used to determine where cells from a 
certain cell type end up in the PCA ( Fig. 2 e). Plotting each time 
point separately allowed for visualization of the monocyte expres-
sion patterns over time. Contributions of each surface marker and 
correlations between surface marker expression patterns were vi-
sualized by plotting the loadings of each marker as arrows in the 
scatterplots. As loadings cannot exceed the value of 1, they were 
multiplied by 10 for easier visualization in the scatter plots.
 Plasma Chemokine Concentrations 
 EDTA-anticoagulated blood was centrifuged immediately at 
2,000  g for 15 min at 4   °   C, and plasma was stored at –80   °   C until 
analysis. CCL2, CCL3 and CCL4 plasma levels were determined 
using a Luminex assay according to the manufacturer’s instruc-
tions (MILLIPLEX; Merck Millipore, Billerica, MA, USA).
CX 3 CL1 plasma levels were determined by ELISA according to the 
manufacturer’s instructions (R&D Systems).
 Software and Statistics 
 Flow cytometry data were analysed using FCS Express V5 and 
R version 3.1.2. Statistical analysis was performed using Prism 6.07 
(GraphPad Software, La Jolla, CA, USA). Statistical significance of 
MFIs and HLA-DR percentages were assessed using repeated-
measures 2-way ANOVA with Dunnett’s correction for multiplic-
ity, and statistical significance of plasma cytokine levels was deter-
mined using Friedman’s test with Dunn’s correction for multiplic-
ity. Statistical significance of cell numbers was assessed by multiple 
Mann-Whitney tests with Bonferroni correction for multiplicity as 
not all time points were measured in all volunteers, precluding the 
use of repeated-measures tests.
 Results 
 Monocyte Subset Numbers during Experimental 
Endotoxemia 
 Volunteers injected with LPS showed clinical symp-
toms as described previously (data not shown)  [13, 15] . 
In short, an increase in symptom scores (headache, nau-
sea, and muscle/back ache) occurs at 1.5–2 h after LPS 
injection. At the same time, the body core temperature 
was elevated until 8 h after LPS injection. After objective 
symptoms had decreased at 2.5 h, the heart rate became 
elevated and the mean arterial pressure decreased, which 
lasted until at least 7–8 h after LPS injection. Cell num-
bers in the peripheral blood of most cell types and subsets 
are changed after LPS injection. Neutrophilia was ob-
served within 3 h after injection, leading to an increase in 
total white blood cell counts ( Fig. 1 ). Neutrophil and total 
white blood cell counts returned to normal values at 24 h 
after LPS injection.
 Total blood monocyte counts were reduced at 1–1.5 h 
after LPS injection and showed a trend towards increased 
numbers at 6–8 h after LPS injection. The kinetics of CM 
after LPS injection reflected those of the total monocyte 
population with only 2% of CM remaining in circulation 
at 90 min after challenge. This similarity in kinetics was 
not surprising since 80–90% of all monocytes are CM un-
der homeostatic conditions.
 IM and NCM showed a different picture. For IM, 97–
99% were lost from circulation between 1 and 1.5 h after 
LPS injection, and the first IM returned into the periph-
eral blood 6–8 h after LPS injection. IM numbers showed 
a marked increase 24 h after LPS injection compared to 
homeostatic numbers. NCM numbers also decreased 1–
8 h after LPS injection. However, during the first 2 h, the 
decrease in NCM numbers was not as large as for the oth-
er 2 subsets, which was reflected by the finding that at
1.5 h after LPS injection 30–50% of all monocytes were 
NCM. At 24 h after LPS injection, NCM numbers had 
returned to normal levels.
 Fig. 2. Multidimensional single-cell analysis. Principal component 
analysis (PCA) was performed on fluorescence intensities of for-
ward scatter (FSC) high /sideward scatter (SSC) low -gated CD3/
CD19/CD56 neg mononuclear cells. PCA was performed with ( a ) 
and without ( b ) taking CD14 and CD16 into account. Arrows in-
dicate loadings, i.e., the arrow for CX 3 CR1 points to the right, in-
dicating that this marker is highly expressed on cells with a high 
object score in PC1 (which, thus, are on the right side of the figure). 
The length of the arrow indicates how much its parameter contrib-
utes to the PCA. Percentages on the  x and  y  axes indicate the per-
centage of variance in the dataset explained by each PC. To assess 
where each subset is localized in the PCA, cells were gated on a 
traditional CD14/CD16 plot ( c ) and plotted in the PCA without 
CD14/CD16 ( d ), showing a separation between classical mono-
cytes (CM), intermediate monocytes (IM) and non-classical 
monocytes (NCM). When plotting individual time points in the 
PCA ( e ) without CD14/CD16, the loss of CM at t = 1.5 h and the 
loss of IM and NCM from 1.5/3–8 h after lipopolysaccharide injec-
tion can clearly be observed. Data are from 1 individual represen-
tative for a total of 6 donors. MFI, median fluorescence intensity. 
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 Loss of Monocyte Subsets Is Independent of CD14 and 
CD16 Expression 
 NCM have been shown to lose CD16 expression after 
stimulation with LPS in vitro  [18] . Therefore, we identi-
fied the 3 monocyte subsets without the use of the classi-
cal markers CD14 and CD16. This was done by using 
multidimensional single-cell analysis after the cells were 
stained with multiple markers that can identify monocyte 
subsets and monocyte activation status: CCR2, CX 3 CR1, 
CD38, HLA-DR, CD62L, CD163, CD64 and the DC 
markers CD1c and CD303. PCA reduces the number of 
dimensions in a dataset by finding correlations between 
marker expressions and replacing the markers by a small-
er number of imaginary markers called PCs. In this case, 
it reduced the number of dimensions required for visual-
ization from 11 or 9 (1 for each measured antibody) to 2 
dimensions (PC1 and PC2). Resulting values for PCA1 
and PCA2 (called object scores) were adequate to dis-
criminate between the 3 subsets ( Fig. 2 a, b), either with or 
without the use of CD14 and CD16. Arrows indicate the 
loadings for each marker, meaning that when an arrow 
points right, such as CX 3 CR1, all cells on the right of the 
plot (positive value in PCA1) have a relatively high
CX 3 CR1 expression, whereas cells on the left of the plot 
(negative value for PCA1) have a relatively low CX 3 CR1 
expression. The length of the arrow indicates how impor-
tant a marker is for the PCA and shows that dendritic cell 
markers CD1c and CD303 are least important for ex-
plaining differences in expression between monocytes, as 
would be expected. Plotting of CD14/CD16-gated CM, 
IM and NCM from t = 0 in the PCA space performed 
without CD14 and CD16 showed where the subsets end 
up in the PCA ( Fig. 2 d). The different cell populations 
matched the known expression profiles for each subset. 
For example, NCM have the highest CX 3 CR1 expression, 
IM have the highest HLA-DR expression and CM have 
the highest CD62L expression.
 When plotting all time points separately, multidimen-
sional analysis without the use of CD14 and CD16 showed 
similar kinetics to those in  Figure 1 ( Fig. 2 e). Thus, mul-
tidimensional analysis demonstrated that the observed 
loss of IM and NCM at t = 3–8 h cannot be attributed to 
(LPS-induced) activation-induced loss of CD16 expres-
sion.
 Of interest is that the multidimensional plots showed 
that the CM population present at t = 3–8 h after LPS in-
jection was shifted to the left compared to t = 0. This sug-
gests a change in expression for some of the markers, such 
as an increased expression of markers with a negative 
loading for PCA1 (i.e., the arrow pointing left, like
CD62L, CD38 and CD64) or a decreased expression
of markers with a positive loading for PCA1 (such as
CX 3 CR1 and, to a lesser extent, HLA-DR).
 Differential Monocyte Surface Marker Expression 
after LPS Injection 
 Since multidimensional analysis of monocyte subsets 
indicated changes in monocyte surface marker expres-
sion, expression levels of several activation and differen-
tiation markers were compared over time for each subset 
( Fig. 3 ). This analysis showed reduced expression of che-
mokine receptor CX 3 CR1 on all subsets during the first
8 h after challenge. Adhesion molecules Mac-1 (CD11b) 
and  L -selectin (CD62L) showed increased expression, the 
former on CM and IM and the latter on IM and NCM. 
Monocyte activation/differentiation markers showed ei-
ther upregulation (CD11b on CM and IM), downregula-
tion (CD86 on IM and NCM) or no significant changes 
(CD80). CD163 expression was increased at 24 h after 
LPS injection on all 3 subsets. HLA-DR expression and 
the percentage of HLA-DR-positive cells was decreased 
only on IM and NCM and not on CM.
 Plasma Chemokine Concentrations 
 Plasma chemokine concentrations were determined at 
several time points after injection of LPS ( Fig. 4 ). Chemo-
kine levels in plasma were significantly increased from
1 h (CCL3 and CCL4) and 2 h (CCL2, CX 3 CL1) after LPS 
injection. CX 3 CL1 plasma levels were the highest of the 4 
measured cytokines and increased more slowly than 
those of the other chemokines. CX 3 CL1 levels reached 
their highest levels at 6 h after LPS injection, a time point 
at which plasma CCL2 and CCL3 levels had already re-
turned to normal levels. Plasma CCL4 levels also reached 
their maximum very rapidly but remained elevated until 
at least 6 h after LPS injection.
 Discussion 
 Differential Loss of Monocyte Subsets from Circulation 
after Systemic LPS Challenge 
 The changes in monocyte subset counts are in agree-
ment with those published previously on the whole mono-
cyte population  [13] and on the 3 subsets  [14] . However, 
the larger number of measurements in our study allowed 
for a better overview of the loss of cells during the first 
hours after LPS injection and of the increased CM num-
bers 8 h after LPS injection. Furthermore, the multidi-
mensional FACS analysis allowed us to demonstrate that 
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our findings are unlikely to be due to the loss of CD14 or 
CD16 expression, as was described in vitro  [18] .
 Our measurements at the time point 24 h after LPS in-
jection show similarities to those observed in disease, as 
recent studies described increased percentages of IM  [6] 
or both IM and NCM  [7, 8] in sepsis  [6, 7] , tuberculosis 
infection  [8] and a large number of other infectious and 
inflammatory diseases (reviewed in  [1] ).
 Increases in cell numbers might reflect the mobiliza-
tion of marginated cells or a compensatory release of cells 
**
**** *
****
****
****
****
*
********
**** ** *
**** ***
*
102
0 2 4 6
HLA-DR
8 24
103
104
105
M
FI
102
0 2 4 6
CD69
8 24
103
104
105
M
FI
102
0 2 4 6
CD38
8 24
103
104
105
M
FI
102
0 2 4 6
CX3CR1
8 24
103
104
105
M
FI
****
********
****
***
*******
****
*** ***
*
102
0 2 4 6
CD86
8 24
103
104
105
M
FI
102
0 2 4 6
CD64
8 24
103
104
105
M
FI
102
0 2 4 6
CD163
8 24
103
104
105
M
FI
102
0 2 4 6
Time after LPS, h Time after LPS, h Time after LPS, h
Time after LPS, hTime after LPS, hTime after LPS, h
Time after LPS, h Time after LPS, h Time after LPS, h
Time after LPS, hTime after LPS, hTime after LPS, h
CCR2
8 24
103
104
105
M
FI ***
****
*
****
**
*
*
**** ****
**
*
0
20
40
60
80
0 2 4 6
HLA-DR+ cells
8 24
100
Ce
lls
, %
102
0 2 4 6
CD80
8 24
103
104
105
M
FI
102
0 2 4 6
CD62L
8 24
103
104
105
M
FI
102
0 2 4 6
CD11b CM
IM
NCM
8 24
103
104
105
M
FI
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
 Fig. 3. Surface marker expression patterns after lipopolysaccharide 
(LPS) injection. Surface marker expressions were determined on 
classical monocytes (CM), intermediate monocytes (IM) and non-
classical monocytes (NCM) separately. For HLA-DR, the percent-
age of HLA-DR + cells was examined as well. Data points are 
nudged ±0.2 days for better representation of error bars and indi-
cate means ± SEM.  * ,  * * ,  * * * and  * * * * indicate  p < 0.05,  p < 0.01,
 p < 0.001 and  p < 0.0001 compared to t = 0, respectively.  n = 6 per 
time point. MFI, median fluorescence intensity. 
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from the bone marrow, where large numbers of mono-
cytes reside. This bone marrow monocyte pool is en-
riched by IM-like cells  [19] , which might explain a much 
larger fold increase in IM numbers than in CM numbers 
after LPS injection. Alternatively, the increase in cell 
numbers might reflect de novo production of monocytes 
in the bone marrow. A labelling study in simian macaques 
 [20] has shown that, under homeostatic conditions, CM 
are the first cells to be released from bone marrow, fol-
lowed by IM and lastly by NCM. In humans, CM are the 
first cells to repopulate the bloodstream after hematopoi-
etic stem cell transplantation  [21] , making it likely that 
human monocytes follow a similar pattern. This would fit 
with our observations that CM numbers are elevated first, 
followed by IM. NCM numbers were not significantly el-
evated, which might be attributed to the longer NCM 
maturation time  [20, 21] . However, if the increased cell 
numbers observed in our study were caused by de novo 
production, monocyte maturation would have to be rap-
idly increased, as monocyte maturation appears to take 2 
days (CM), 4 days (IM) or 7 days (NCM) under homeo-
static conditions  [20] .
 In contrast to later time points, we observed a dramat-
ic loss of monocytes from the circulation during the early 
phases of inflammation. This decrease in monocyte num-
bers might reflect an increase in monocytes residing in 
the marginated pool  [22] or rolling on the vessel walls 
 [23] , a process described under inflammatory conditions 
 [3, 24] . For NCM, the decreased numbers could also re-
flect a larger fraction of monocytes displaying patrolling 
behaviour as described during inflammation  [3] . Alterna-
tively, at least part of the monocytes might exit the blood-
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 Fig. 4. Plasma chemokine concentrations. Plasma CCL2 ( a ), CCL3 ( b ), CCL4 ( c ) and CX 3 CL1 ( d ) after lipopoly-
saccharide (LPS) injection. Data represent means ± 95% CI with  n = 11. Dotted lines indicate detection limits; 
detection limits for CCL4 and CX 3 CL1 were below the  x  axis.  * ,  * * and  * * * * represent  p < 0.05,  p < 0.01 and  p < 
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stream and differentiate into dendritic cells or macro-
phages as described for murine CM during homeostasis 
 [25] .
 Diurnal rhythms should also be taken into account 
when comparing cell numbers at different time points, as 
circulating CM and IM numbers have been shown to vary 
by 20 and 40% during the day, respectively  [26] . Our time 
point 0 (09: 00 a.m.) is close to the diurnal minimum of 
both CM and NCM. At time points reported to have a 
higher monocyte count due to diurnal variation, mono-
cyte numbers after LPS injection were either decreased 
(IM, t = 8 h) or not analysed (t = 14 h). Thus, diurnal 
variations do not account for the differences in monocyte 
counts observed after LPS injection.
 Plasma Chemokine Levels Parallel Differential Loss of 
Monocyte Subsets from the Circulation 
 Activation of chemokine receptors CCR2, CCR5 and 
CX 3 CR1 by their ligands (CCL2, CCL3/CCL4 and
CX 3 CL1, respectively) can induce monocyte extravasa-
tion  [27, 28] . In addition, CX 3 CL1 is reported to increase 
NCM patrolling  [29] in mice, which would also lead to an 
observed loss of NCM flowing freely in the blood. The 
kinetics of plasma CCL2 levels were inversely proportion-
al to the presence of CM in the blood, the subset with the 
highest CCR2 expression. Similar to this, plasma concen-
trations of CCR5 ligand CCL4 correlated with the de-
crease in IM numbers, which have the highest CCR5 ex-
pression. CX 3 CL1 levels, in turn, follow the loss of NCM, 
which have the highest CX 3 CR1 expression. In contrast, 
concentrations of CCR5 ligand CCL3 were the lowest of 
all measured cytokines and appear to return to normal 
levels more rapidly than IM numbers, indicating that this 
chemokine is not providing the primary signal for IM to 
exit from the circulation. Taken together, these data sug-
gest that CCL2, CCL4 and CX 3 CL1 but not CCL3 were 
involved in the loss of monocytes from the circulation 
during LPS-induced acute inflammation. However, proof 
of this hypothesis would require a study utilizing chemo-
kine-blocking antibodies in the context of experimental 
endotoxemia.
 Monocyte Activation and Differentiation Markers 
 Circulating monocytes did not show a clear activated 
phenotype after LPS challenge. CD11b expression was in-
creased in CM and IM, as published previously  [14] , but 
CD86 and CD62L showed significant changes, pointing 
towards a lower activation status. A decreased activation 
state might be due to activated cells homing to the tissues 
leaving behind less activated cells. A similar situation in 
which only cells with a low activation state remain in the 
circulation has been proposed for both neutrophils  [30] 
and eosinophils  [31] . This notion is further supported by 
the finding that the chemokine receptor CX 3 CR1 had a 
lower expression in the NCM remaining in the circula-
tion after induction of acute inflammation. Alternatively, 
however, the decrease in CX 3 CR1 expression could be 
due to receptor endocytosis after ligand binding or re-
populating of monocytes with differential receptor ex-
pression from a bone marrow pool, although this latter 
option would require an extreme increase in monocyte 
maturation rates, as NCM maturation under homeostasis 
is in the order of several days, not hours  [20] .
 HLA-DR is a marker of special interest, as a decreased 
monocyte HLA-DR expression has been shown to corre-
late with the development of sepsis after severe acute in-
flammation  [32, 33] . However, HLA-DR expression on 
CM remained stable during our whole experiment. This 
finding illustrates the need to perform measurements on 
gated monocyte subsets instead of on the whole mono-
cyte population, as loss of HLA-DR during experimental 
endotoxemia is caused, first, by a loss of all monocytes 
from the circulation and, later, by both a loss of HLA-
DR high cells and a lower expression of HLA-DR on the 
remaining HLA-DR high cells.
 Conclusions 
 The experimental endotoxemia model uniquely al-
lowed the analysis of the earliest stages of acute inflam-
mation and provided critical new insights into the behav-
iour of circulatory monocytes at time points at which pa-
tients normally cannot be sampled. Monocyte kinetics 
during these early stages of LPS-induced acute inflamma-
tion differ greatly from later phases of the inflammatory 
response. More than 95% of cells from all 3 monocyte 
subsets were lost from the circulation at 1–2 h after LPS 
injection, during which the cells remaining in the blood-
stream did not display a clear activated phenotype. This 
decrease was followed by an increase in monocyte counts 
and, finally, by a return to baseline levels, but with differ-
ences in timing for the 3 monocyte subsets. Taken togeth-
er, our experiments revealed marked differences in the 
behaviour of the 3 monocyte subsets during the earliest 
phases of the acute inflammatory response.
 Monocyte Kinetics in Experimental 
Endotoxemia 
 J Innate Immun 2017;9:464–474 
DOI: 10.1159/000475665
473
 References 
 1 Wong KL, Yeap WH, Tai JJ, Ong SM, Dang 
TM, Wong SC: The three human monocyte 
subsets: implications for health and disease. 
Immunol Res 2012; 53: 41–57. 
 2 Ziegler-Heitbrock L, Ancuta P, Crowe S, 
Dalod M, Grau V, Hart DN, Leenen PJ, Liu 
YJ, MacPherson G, Randolph GJ, Scherberich 
J, Schmitz J, Shortman K, Sozzani S, Strobl H, 
Zembala M, Austyn JM, Lutz MB: Nomencla-
ture of monocytes and dendritic cells in 
blood. Blood 2010; 116:e74–e80. 
 3 Cros J, Cagnard N, Woollard K, Patey N, 
Zhang SY, Senechal B, Puel A, Biswas SK, Mo-
shous D, Picard C, Jais JP, D’Cruz D, Casa-
nova JL, Trouillet C, Geissmann F: Human 
CD14dim monocytes patrol and sense nucle-
ic acids and viruses via TLR7 and TLR8 recep-
tors. Immunity 2010; 33: 375–386. 
 4 Weber C, Belge KU, von Hundelshausen P, 
Draude G, Steppich B, Mack M, Frankenberg-
er M, Weber KS, Ziegler-Heitbrock HW: Dif-
ferential chemokine receptor expression and 
function in human monocyte subpopula-
tions. J Leukoc Biol 2000; 67: 699–704. 
 5 Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, 
Spanbroek R, Llodra J, Garin A, Liu J, Mack 
M, van Rooijen N, Lira SA, Habenicht AJ, 
Randolph GJ: Monocyte subsets differentially 
employ CCR2, CCR5, and CX3CR1 to accu-
mulate within atherosclerotic plaques. J Clin 
Invest 2007; 117: 185–194. 
 6 Poehlmann H, Schefold JC, Zuckermann-
Becker H, Volk HD, Meisel C: Phenotype 
changes and impaired function of dendritic 
cell subsets in patients with sepsis: a prospec-
tive observational analysis. Crit Care 2009; 
 13:R119. 
 7 Skrzeczynska J, Kobylarz K, Hartwich Z, 
Zembala M, Pryjma J: CD14 + CD16 + mono-
cytes in the course of sepsis in neonates and 
small children: monitoring and functional 
studies. Scand J Immunol 2002; 55: 629–638. 
 8 Castano D, Garcia LF, Rojas M: Increased fre-
quency and cell death of CD16 + monocytes 
with  Mycobacterium tuberculosis infection. 
Tuberculosis (Edinb) 2011; 91: 348–360. 
 9 Rodriguez-Munoz Y, Martin-Vilchez S, Lo-
pez-Rodriguez R, Hernandez-Bartolome A, 
Trapero-Marugan M, Borque MJ, Moreno-
Otero R, Sanz-Cameno P: Peripheral blood 
monocyte subsets predict antiviral response 
in chronic hepatitis C. Aliment Pharmacol 
Ther 2011; 34: 960–971. 
 10 Zhang JY, Zou ZS, Huang A, Zhang Z, Fu JL, 
Xu XS, Chen LM, Li BS, Wang FS: Hyper-ac-
tivated pro-inflammatory CD16 monocytes 
correlate with the severity of liver injury and 
fibrosis in patients with chronic hepatitis B. 
PLoS One 2011; 6:e17484. 
 11 Han J, Wang B, Han N, Zhao Y, Song C, Feng 
X, Mao Y, Zhang F, Zhao H, Zeng H: CD-
14 high CD16 + rather than CD14 low CD16 + 
monocytes correlate with disease progression 
in chronic HIV-infected patients. J Acquir 
Immune Defic Syndr 2009; 52: 553–559. 
 12 Andreasen AS, Krabbe KS, Krogh-Madsen R, 
Taudorf S, Pedersen BK, Moller K: Human 
endotoxemia as a model of systemic inflam-
mation. Curr Med Chem 2008; 15: 1697–1705. 
 13 Kamp VM, Leentjens J, Pillay J, Langereis JD, 
de Kleijn S, Kox M, Netea MG, Pickkers P, 
Koenderman L: Modulation of granulocyte 
kinetics by GM-CSF/IFN-γ in a human LPS 
rechallenge model. J Leukoc Biol 2013; 94: 
 513–520. 
 14 Thaler B, Hohensinner PJ, Krychtiuk KA, 
Matzneller P, Koller L, Brekalo M, Maurer G, 
Huber K, Zeitlinger M, Jilma B, Wojta J, 
Speidl WS: Differential in vivo activation of 
monocyte subsets during low-grade inflam-
mation through experimental endotoxemia 
in humans. Sci Rep 2016; 6: 30162. 
 15 Leentjens J, Kox M, Koch RM, Preijers F, 
Joosten LA, van der Hoeven JG, Netea MG, 
Pickkers P: Reversal of immunoparalysis in 
humans in vivo: a double-blind, placebo-con-
trolled, randomized pilot study. Am J Respir 
Crit Care Med 2012; 186: 838–845. 
 16 Kox M, van Eijk LT, Zwaag J, van den Wilden-
berg J, Sweep FC, van der Hoeven JG, Pick-
kers P: Voluntary activation of the sympathet-
ic nervous system and attenuation of the in-
nate immune response in humans. Proc Natl 
Acad Sci USA 2014; 111: 7379–7384. 
 17 Jansen JJ, Hilvering B, van den Doel A, Pick-
kers P, Koenderman L, Buydens LMC, van 
den Brink OF: FLOOD: FLow cytometric Or-
thogonal Orientation for Diagnosis. Che-
mometr Intell Lab Syst 2016; 151: 126–135. 
 18 Picozza M, Battistini L, Borsellino G: Mono-
nuclear phagocytes and marker modulation: 
when CD16 disappears, CD38 takes the stage. 
Blood 2013; 122: 456–457. 
 19 Mandl M, Schmitz S, Weber C, Hristov M: 
Characterization of the CD14 ++ CD16 + mono-
cyte population in human bone marrow. 
PLoS One 2014; 9:e112140. 
 20 Sugimoto C, Hasegawa A, Saito Y, Fukuyo Y, 
Chiu KB, Cai Y, Breed MW, Mori K, Roy CJ, 
Lackner AA, Kim WK, Didier ES, Kuroda MJ: 
Differentiation kinetics of blood monocytes 
and dendritic cells in macaques: insights to 
understanding human myeloid cell develop-
ment. J Immunol 2015; 195: 1774–1781. 
 21 McGovern N, Schlitzer A, Gunawan M, Jar-
dine L, Shin A, Poyner E, Green K, Dickinson 
R, Wang XN, Low D, Best K, Covins S, Milne 
P, Pagan S, Aljefri K, Windebank M, Miran-
da-Saavedra D, Larbi A, Wasan PS, Duan K, 
Poidinger M, Bigley V, Ginhoux F, Collin M, 
Haniffa M: Human dermal CD14 + cells are a 
transient population of monocyte-derived 
macrophages. Immunity 2014; 41: 465–477. 
 22 van Furth R, Sluiter W: Distribution of blood 
monocytes between a marginating and a cir-
culating pool. J Exp Med 1986; 163: 474–479. 
 23 Ramos CL, Huo Y, Jung U, Ghosh S, Manka 
DR, Sarembock IJ, Ley K: Direct demonstra-
tion of P-selectin- and VCAM-1-dependent 
mononuclear cell rolling in early atheroscle-
rotic lesions of apolipoprotein E-deficient 
mice. Circ Res 1999; 84: 1237–1244. 
 24 Xu H, Manivannan A, Crane I, Dawson R, Li-
versidge J: Critical but divergent roles for 
CD62L and CD44 in directing blood mono-
cyte trafficking in vivo during inflammation. 
Blood 2008; 112: 1166–1174. 
 25 Varol C, Landsman L, Fogg DK, Greenshtein 
L, Gildor B, Margalit R, Kalchenko V, Geiss-
mann F, Jung S: Monocytes give rise to muco-
sal, but not splenic, conventional dendritic 
cells. J Exp Med 2007; 204: 171–180. 
 Acknowledgements 
 Our gratitude goes to the research nurses of the Radboud Med-
ical Center for taking excellent care of our volunteers and to Deon 
Kanters for his help with chemokine measurements. This work 
was supported by the Dutch Lung Foundation (grant 3.2.10.052).
 Disclosure Statement 
 The authors declare no conflicts of interest.
 Author Contributions 
 R.G. took care of all clinical aspects of the trial, including re-
cruitment and screening of volunteers and the endotoxemia chal-
lenge itself, under supervision of P.P. T.T. performed all labora-
tory and statistical analyses under supervision of L.K. and wrote 
the first draft of the paper. All authors read and approved the final 
manuscript.
 
 Tak/van Groenendael/Pickkers/
Koenderman
 
 J Innate Immun 2017;9:464–474 
DOI: 10.1159/000475665
474
 26 Shantsila E, Tapp LD, Wrigley BJ, Montoro-
Garcia S, Ghattas A, Jaipersad A, Lip GY: 
The effects of exercise and diurnal variation 
on monocyte subsets and monocyte-platelet 
aggregates. Eur J Clin Invest 2012; 42: 832–
839. 
 27 Kuziel WA, Morgan SJ, Dawson TC, Griffin 
S, Smithies O, Ley K, Maeda N: Severe reduc-
tion in leukocyte adhesion and monocyte ex-
travasation in mice deficient in CC chemo-
kine receptor 2. Proc Natl Acad Sci USA 1997; 
 94: 12053–12058. 
 28 Auffray C, Fogg DK, Narni-Mancinelli E, 
Senechal B, Trouillet C, Saederup N, Leemput 
J, Bigot K, Campisi L, Abitbol M, Molina T, 
Charo I, Hume DA, Cumano A, Lauvau G, 
Geissmann F: CX3CR1 + CD115 + CD135 + 
common macrophage/DC precursors and the 
role of CX3CR1 in their response to inflam-
mation. J Exp Med 2009; 206: 595–606. 
 29 Auffray C, Fogg D, Garfa M, Elain G, Join-
Lambert O, Kayal S, Sarnacki S, Cumano A, 
Lauvau G, Geissmann F: Monitoring of blood 
vessels and tissues by a population of mono-
cytes with patrolling behavior. Science 2007; 
 317: 666–670. 
 30 Hietbrink F, Koenderman L, Althuizen M, 
Leenen LP: Modulation of the innate immune 
response after trauma visualised by a change 
in functional PMN phenotype. Injury 2009; 
 40: 851–855. 
 31 Johansson MW, Han ST, Gunderson KA, 
Busse WW, Jarjour NN, Mosher DF: Platelet 
activation, P-selectin, and eosinophil β1-
integrin activation in asthma. Am J Respir 
Crit Care Med 2012; 185: 498–507. 
 32 Hershman MJ, Cheadle WG, Wellhausen SR, 
Davidson PF, Polk HC Jr: Monocyte HLA-DR 
antigen expression characterizes clinical out-
come in the trauma patient. Br J Surg 1990; 77: 
 204–207. 
 33 Hershman MJ, Cheadle WG, Kuftinec D, Polk 
HC Jr, George CD: An outcome predictive 
score for sepsis and death following injury. 
Injury 1988; 19: 263–266. 
 
